Core Peptides Appears in 33.6% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide Suppliers. For more detail, you can also read Peptide Suppliers: AI Visibility Discovery Index.
On this report
Browse sections
- Answer Capsule
- Current AI visibility
- What changed since last month
- Next Step
- Step 1. Measure
- Step 2. Make the website consistent
- Step 3. Align the external narrative
- Step 4. Optimize priority company pages
- Step 5. Publish around buyer questions
- Our 90-day action plan
- Methodology
- Our first three priorities
- Related research
- Learn More
Key Takeaways
- Core Peptides is mentioned in 33.55% of benchmark answers, but only 15.89% of those answers recommend it.
- The main issue is the gap between being cited and being endorsed, not overall reach.
- Several AI answers contain conflicting claims about availability, Trustpilot presence, purity, and discounts.
- The plan prioritizes fact-checking, website consistency, third-party source review, and content built around buyer comparison questions.
Answer Capsule
In November 2026, Core Peptides appeared in 152 of 453 AI answers included in the Peptide Suppliers benchmark (33.55%). It received 72 recommendations (15.89%), with 59 Top 3 placements and 17 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.
Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. This edition establishes a research baseline. It does not claim a change from earlier editions measured on a different basis. Conflicting AI claims require verification before corrections are proposed.
Current AI visibility
Questions This Section Answers
- How do Core Peptides mentions, recommendations and placements compare with its Peptide Suppliers peers?
Core Peptides recorded 152 mentions (33.55%) and 72 recommendations (15.89%) across 453 answers included in the benchmark. Top 3 placements numbered 59; first-place recommendations numbered 17. Framing among its mentions was 79 positive, 69 neutral and 4 negative.
Rank | Company | Mentions | Mention rate | Recommendations | Recommendation rate | Top 3 | Top 3 rate | #1 | #1 rate |
|---|---|---|---|---|---|---|---|---|---|
1 | Phoenix Pharmaceuticals | 178 | 39.29% | 117 | 25.83% | 94 | 20.75% | 58 | 12.80% |
2 | Biotech Peptides | 142 | 31.35% | 91 | 20.09% | 70 | 15.45% | 28 | 6.18% |
3 | Core Peptides | 152 | 33.55% | 72 | 15.89% | 59 | 13.02% | 17 | 3.75% |
4 | AminoVault | 33 | 7.28% | 27 | 5.96% | 17 | 3.75% | 5 | 1.10% |
5 | Peptides Source | 10 | 2.21% | 4 | 0.88% | 3 | 0.66% | 1 | 0.22% |
6 | Blue Sky Peptide | 36 | 7.95% | 3 | 0.66% | 3 | 0.66% | 0 | 0.00% |
7 | Peptide Tech | 7 | 1.55% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
Core Peptides appears in roughly a third of the benchmark answers and is named among the three most visible companies, yet its recommendation rate sits well below the two firms ahead of it. That gap between being seen and being endorsed is the central business issue: reach is already strong, so the work should focus on what answers say when they endorse.
Placement is thinner still. Most of its appearances are mentions rather than affirmative recommendations, and first-place finishes are a small slice of the total. The agency would build a scorecard that tracks mentions, recommendations and placement separately, so the client can see which measure moves and avoid reading a mention as an endorsement.
What changed since last month
Questions This Section Answers
- How did Core Peptides counts and coverage differ across the available monthly snapshots?
Metric | Nov 2026 |
|---|---|
Mentions | 152 / 453 (33.55%) |
Recommendations | 72 / 453 (15.89%) |
Top 3 recommendations | 59 / 453 (13.02%) |
#1 recommendations | 17 / 453 (3.75%) |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
This edition is the first broad baseline, so the monthly figures describe one selected sample rather than a trend. Earlier editions drew on a narrower question set, which means the current totals are not directly comparable with the archived months. The agency would treat this month as the reference point and compare future editions only once they use the same screening scope.
That framing matters for expectations. A later edition with a different answer total will not by itself show why counts or rates moved, and the agency would report the observed movement and the comparability limit side by side rather than presenting a narrative of improvement or decline.
AI recommendation trend
Observed recommendation rate (%), Nov 2026
- Core Peptidesno changeNov 202615.89%
Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.
/ Take the next step
Want to Understand Your AI Citation Footprint?
We start every engagement with a full audit of how AI systems reference your brand today.
Measurable, Repeatable Programme
Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge
Citation Architecture Review
Identify which high-authority community sources are and aren't working in your favour across AI platforms.
AI Visibility Audit
Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.
Step 1. Measure
Questions This Section Answers
- What should the agency measure and verify first for Core Peptides?
AI answers contained 5 conflicting claims about Core Peptides: 0 critical, 1 high, 4 medium, 0 low. Of these, 1 was rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
The recorded answers carried several conflicting claims about Core Peptides, and one of them was rated high priority for checking. Those ratings order the fact-checking work; they do not establish that the company or any publisher got something wrong. The agency would turn the list into a scoped review register, with each claim assigned an owner, a primary source to check and a status.
A visibility comparison would sit alongside that register. Seeing where Core Peptides is mentioned but not endorsed, and which claims cluster around those answers, gives the client a defensible order of work instead of a broad cleanup.
Step 2. Make the website consistent
Questions This Section Answers
- Which recorded claim differences about Core Peptides should be verified before proposed page edits?
Review topic | Severity | Recorded AI claim A | Recorded AI claim B |
|---|---|---|---|
is it still in business / availability | high | actively operating and recommended as dependable vendor | closed as part of gray-market research vendor crackdown |
Trustpilot presence / review rating | medium | Trustpilot profile removed; only Knoji reviews (4.0/5) | Strong overall rating on Trustpilot |
purity level | medium | ~96-97.5% actual purity, below advertised 99% | ≥99% purity |
sitewide discount percentage | medium | up to 30% off select orders | 10% to 15% off sitewide |
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
The disputed topics are practical ones: whether the company is still operating, its review presence, its stated purity and its discount levels. Each pair of recorded claims is quoted from AI answers, not verified fact, and different collection dates could account for an apparent conflict. The agency would resolve the entity and date first, then check current primary sources before deciding whether any correction is warranted.
Only after that verification would page briefs be drafted. A brief would state the approved fact, the audience question it answers and the evidence behind it, leaving any claim that cannot be confirmed out of the correction queue.
Step 3. Align the external narrative
Questions This Section Answers
- Which cited third-party pages are relevant to fact review for Core Peptides?
Cited page selected for review | Citation appearances in all captured answers | Answers mentioning the company | Conflicting claims linked to this page |
|---|---|---|---|
https://peptidestack.io/blog/core-peptides-review-2026 | 17 | 17 | 3 |
https://peptideresearchreviews.com/articles/core-peptides-vs-roehn-2026 | 9 | 9 | 3 |
https://compoundreview.com/guides/core-peptides-review | 7 | 7 | 2 |
https://realpeptides.co/core-peptides-legit-review-2026/ | 6 | 6 | 2 |
https://knowyourpeptide.com/vendors/core-peptides | 2 | 2 | 2 |
https://reddit.com/r/PeptidesProducts/comments/1o71rs2/my_experience_with_corepeptidesca_they_took_my/ | 10 | 10 | 1 |
These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.
Several cited pages carry more than one of the conflicting claims, and one forum thread is among the most frequently cited sources tied to the company. Citation does not show that a page influenced an answer, and a page linked to a claim is not necessarily its cause. The agency would review the current contents of the listed pages before approaching anyone.
Where a page is genuinely out of date, the agency would prepare an evidence-backed request describing the specific correction and the source supporting it. Where the page is accurate or the claim is unverifiable, the outcome is a documented no-change decision rather than a request.
Step 4. Optimize priority company pages
Questions This Section Answers
- Which observed Core Peptides website pages should receive review briefs?
Company website page | Citation appearances in all captured answers | Benchmark answers citing the page | Recommending answers citing the page |
|---|---|---|---|
https://corepeptides.com/ | 25 | 25 | 1 |
https://corepeptides.com/about-us/ | 9 | 9 | 0 |
https://corepeptides.com/contact-us/ | 5 | 5 | 0 |
https://corepeptides.com/peptides/ | 4 | 4 | 0 |
https://corepeptides.com/peptides/ipamorelin-5mg/ | 3 | 3 | 1 |
https://corepeptides.com/?oid=341&pid=4187&tid=102b3e61cd23ec5d5a67055d829f7f | 2 | 2 | 0 |
https://corepeptides.com/peptides/cjc-1295-ipamorelin-10mg-blend/ | 2 | 2 | 0 |
https://corepeptides.com/peptides/kisspeptin-10mg/ | 2 | 2 | 2 |
The company's website was cited 77 times across 30 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.
The company's own site is cited often, but very few of those citations appear in answers that also recommend the company. That pattern suggests the site is being used as a reference rather than as a reason to endorse, though the evidence cannot confirm why. The agency would start with the homepage and about page, since they carry most of the citations, and treat product pages as secondary.
Page briefs would draw only on approved facts and would address the questions buyers actually ask. Existing coverage would be checked before any new page is proposed, and the briefs would be reviewed by the client before publication.
Step 5. Publish around buyer questions
Questions This Section Answers
- Which observed buyer questions support content briefs for Core Peptides?
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the most popular peptide brands? | 4 | 4 | 4 |
What is the best peptide company in the US? | 5 | 3 | 3 |
What are the best peptide companies in the US? | 4 | 2 | 2 |
What are the best peptide shops? | 3 | 2 | 2 |
What are the most trusted peptide companies? | 4 | 2 | 2 |
What is the alternative to Swiss Chem? | 2 | 2 | 2 |
What is the best company to buy peptides from? | 3 | 2 | 2 |
What is the best peptide company to buy from? | 2 | 2 | 2 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
The recorded questions are brand-comparison and trust questions: which companies are most popular, most trusted or best in the US, and what the alternative to a named competitor is. Core Peptides appears in most of these answers and is recommended in many of them, which makes this a reasonable area for content work. These are answer observations, not search volume or proof of missing pages.
The agency would check whether the site already addresses these questions, then draft briefs for the gaps. Each brief would answer one buyer question directly, using approved facts and clear comparisons, and would be reviewed before anything is published.
Our 90-day action plan
Questions This Section Answers
- How should the agency sequence the proposed Core Peptides work and judge completion?
Period | Deliverable | Completion criterion |
|---|---|---|
Days 1–30 | Baseline scorecard, scoped fact-review register and page/source shortlist | Each record has an owner, evidence requirement and review status |
Days 31–60 | Approved page briefs and justified publisher requests | Separate confirmed edits, no-change decisions, requests and responses |
Days 61–90 | Buyer-content briefs and a fresh scorecard | Record work completed separately from measured answer outcomes and comparability limits |
The first month establishes the baseline scorecard, the scoped fact-review register and the shortlist of pages and sources to examine. Each record needs an owner, an evidence requirement and a review status before work moves on. Nothing in this phase depends on assuming a claim is wrong.
The second month produces approved page briefs and any justified publisher requests, with confirmed edits, no-change decisions, requests and responses recorded separately. The third month adds buyer-question content briefs and a fresh scorecard. Completed work is reported apart from measured answer outcomes, and no visibility gain is promised.
Methodology
Questions This Section Answers
- How are Core Peptides answer metrics and citation populations defined?
This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 453 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.
An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.
The wider citation analysis covers 554 captured answers and 3581 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Nov 2026 | 453 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.
Future editions using the same screening scope can be compared against this baseline.
The answers were collected for this reporting month, though the exact collection dates are unverified. A company counts as recommended only when an answer endorses it with positive wording, and placement counts sit inside recommendations rather than adding to them. Answers can cover several companies, so company totals do not sum to distinct answers.
Sentiment describes answer wording, not customer satisfaction. The citation analysis covers a wider set of captured answers than the benchmark, and cited pages still need independent checking. Future editions using the same screening scope can be compared with this baseline.
Our first three priorities
First, verify the high-priority availability claim and the review-presence question against current primary sources, since those two shape how buyers judge whether the company is active and credible. Second, prepare page briefs for the homepage and about page, where citations concentrate but recommendations are scarce, using only approved facts.
Third, draft buyer-question content around the trust and comparison questions where Core Peptides already appears, checking existing coverage first. Publisher review follows verification, and any request would cite the supporting source. Each step is proposed work with a recorded outcome, not a claim of improved visibility.
Related research
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide Suppliers. For more detail, you can also read Peptide Suppliers: AI Visibility Discovery Index.
/ Learn More
Understanding AI search visibility.
AI search experiences create answers by pulling information from many places online and summarizing it into a single response.


